TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05108714

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous cannulation after intradermal injection of saline via MicronJet600 microneedle device
Description: Intradermal administration of 100 µL saline (registration number РN002134/01 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the right arm, followed by the insertion of 18G catheter in a cubital vein immediately after the saline administration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous cannulation after intradermal injection of lidocaine via MicronJet600 microneedle device (2)
Description: Intradermal administration of 100 µL of lidocaine (registrational number LS001516 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein immediately after the lidocaine administration.
Study: NCT02639962

Intervention type: RADIATION
Intervention: Cardiac CT
Description: Cardiac CT before the CAG, and follow up after 2 month and 12 month

Intervention type: RADIATION
Intervention: Cardiac CT
Description: Cardiac CT before the CAG, and follow up after 2 month and 12 month
Study: NCT05108714

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous cannulation after without prior interventions
Description: insertion of 18G catheter in a cubital vein without prior interventions.
Study: NCT03954132

Intervention type: DRUG
Intervention: Spiolto® Respimat®
Description: Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to Spiolto® Respimat® inhaler by their attending physician in an real-world setting.

Intervention type: DRUG
Intervention: Triple-Therapy (LAMA/LABA/ICS)
Description: Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to any triple therapy Long-acting muscarinic antagonist + Long-acting beta2 adrenoceptor agonist + Inhalative Corticosteroids (LAMA + LABA + ICS) by their attending physician in an real-world setting.
Study: NCT00052780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC or IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01617525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled Feeding Dietary Intervention
Description: All meals will be provided during each 4-week intervention period. Participants must consume all foods provided and must not consume any outside foods during each intervention period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Feeding Dietary Intervention
Description: All meals will be provided during each 4-week intervention period. Participants must consume all foods provided and must not consume any outside foods during each intervention period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Feeding Dietary Intervention
Description: All meals will be provided during each 4-week intervention period. Participants must consume all foods provided and must not consume any outside foods during each intervention period.
Study: NCT02586064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy for PTSD
Description: Relationally focused treatment that focuses on relationship problems that may be caused or maintained by PTSD symptoms. Consists of 12 individual weekly sessions of 45 to 50 minutes. Includes psycho-education, assessing which relationships (or lack of) are causing problems for the Veteran, and addressing the problem areas identified through specific strategies (e.g. communication analysis, decision analysis, role play). Final 2 sessions focus on consolidating what has been learned, what issues remain, identifying types of relationship triggers that could reactivate symptoms, and addressing feelings about termination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure
Description: Aim is to allow Veterans to re-experience traumatic events experienced during military service in a safe and supportive environment, and to re-engage in activities they have been avoiding. 12 individual weekly sessions of 90 minutes. Consists of psychoeducation, breathing retraining, imaginal exposure (repeated imaginal recall of the trauma including sensory details, and associated thoughts and feelings experienced during the trauma), and with trauma, and in vivo exposure (systematically confronting feared and avoided places and activities).
Study: NCT03773367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
Study: NCT01469234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine
Description: loratadine, one 10 mg tablet, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine
Description: fexofenadine, one 180 mg tablet, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to loratadine
Description: one tablet, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to loratadine
Description: one tablet, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to fexofenadine
Description: one tablet, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to fexofenadine
Description: one tablet, orally
Study: NCT06742151

Intervention type: PROCEDURE
Intervention: implant can be placed or not
Description: the possibility of receiving dental implants

Intervention type: PROCEDURE
Intervention: implant can be placed or not
Description: the possibility of receiving dental implants
Study: NCT00423514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT01836965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Intervention
Description: Twelve week manual based social skills curriculum targeting social fluency and responsiveness.
Study: NCT02674776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuZhen Capsule
Description: Patients should take 4 tablet once and 3 times per day for 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Patients should take 4 tablet once and 3 times per day for 3 days.
Study: NCT03516812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cypionate
Description: Given IM
Study: NCT03951714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Marketed experience application on adherence
Description: To evaluate the effect of electronic capture of medication intake through a smartphone app on treatment's adherence

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Marketed experience application on adherence
Description: To evaluate the effect of electronic capture of medication intake through a smartphone app on treatment's adherence
Study: NCT02416219

Intervention type: PROCEDURE
Intervention: Cricoid pressure
Description: participants will ask to mark the place where they will apply cricoid pressure if the patients was undergoing rapid sequence induction. US will be used to confirm how accurate they are in their estimation.

Intervention type: DEVICE
Intervention: Ultrasound
Study: NCT03991858

Intervention type: OTHER
Group type: OTHER
Intervention: Phone call follow-up
Description: A physical therapist made a phone call to the patient one month after his/her initial evaluation at the external rehabilitation clinic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation follow-up
Description: A physical therapist made a direct follow-up through telerehabilitation to the patient one month after his/her initial evaluation at the external rehabilitation clinic
Study: NCT03439657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine GSK1437173A
Description: 2 doses of 0.5 mL of the vaccine in a 0,2 Months schedule. Administered by intramuscular injection into the deltoid muscle of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HZ/su vaccine GSK1437173A
Description: 2 doses of 0.5 mL of the vaccine in a 0,2 Months schedule. Administered by intramuscular injection into the deltoid muscle of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar13
Description: 1 dose of 0.5 mL of the vaccine. Administered by intramuscular injection into the deltoid muscle of the dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13
Description: 1 dose of 0.5 mL of the vaccine. Administered by intramuscular injection into the deltoid muscle of the dominant arm.
Study: NCT04273373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose Albumin
Description: 20% albumin 0.75 g/kg at diagnosis and 0.5 g/kg after 48 hours

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose Albumin
Description: 20% albumin1.5 g/kg at diagnosis and 1 g/kg after 48 hours (duration of infusion 6 hours).
Study: NCT05460260

Intervention type: DEVICE
Intervention: Cascade CGM
Description: 21-days of CGM wear
Study: NCT03945266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: During the intervention, all participants will start out at the Baseline level. The baseline level will last 2 weeks and there will be an assessment to determine weight gain over those 2 weeks. If weight gain has succeeded the recommended amount, participants will be adapted up to a new level of intervention that includes education on GWG, healthy eating and physical activity. After every 4 weeks, an assessment will be performed and adaptations up will be made if necessary. Adaptations include addition of exercise sessions, healthy eating recipe demonstrations, and meal replacements. Participants will weigh themselves daily, wear an activity monitor, record their diet, and complete paper and online surveys.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants will follow the same self-monitoring/assessment schedule but will not receive the GWG, healthy eating, and physical activity education or adaptations.
Study: NCT03206437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: The MBSR course teaches mindfulness meditation skills. This 8-week course meets in person once a week for 2.5 hours. Participants are expected to complete practice assignments at home.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist
Description: This group will wait 8-16 weeks after their first testing visit and after their second study visit is completed they will be able to participate in an 8-week MBSR course.
Study: NCT04117139

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET/MRI
Description: A PET/MRI of the Head and Neck region is done for all patients included in the project.
Study: NCT02362178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thromboelastography to guide blood products infusion
Description: A TEG has been performed before invasive procedure and blood products infusion has been decided according to TEG parameters as follow: fresh frozen plasma (FFP 10 ml/kg) in case of r time\>40 mm and/or platelets (PLTs 10 units/Kg) for MA\<30 mm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care coagulation tests to guide blood products infusion
Description: Patients received FFP (10 ml/kg) if INR\>1.8 and/or PLTS (10 units/Kg) If PLTs count \< 50000/μl
Study: NCT03727425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic assisted bronchoscopy
Description: Robotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
Study: NCT01945827

Intervention type: DEVICE
Intervention: DeltaMaxx Microcoil System
Study: NCT02827916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of neuropathic pain with theThermotest device
Description: Measure of painful neuropathy with thermotest

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of neuropathic pain with SUDOSCAN device
Description: Measure of painful neuropathy with sudoscan Devices

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of neuropathic pain with the Neuropathic Pain Symptom Inventory.
Description: Measure of painful neuropathy with Neuropathic Pain Symptom Inventory.
Study: NCT02933112

Intervention type: DEVICE
Group type: OTHER
Intervention: Auto-titrating mandibular positioner test
Description: Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
Study: NCT04183062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (gemcitabine & docetaxel) plus BIO-11006
Description: BIO-11006 will be administered at a dose of 75 mg twice daily for patients over 5 years of age and under 18 years of age or 125 mg twice daily for patients 18 years of age or older. The study drug will be administered twice daily by nebulizer over 20 minutes.~GemTax will be administered in 21-day cycles. Gemcitabine will be administered at a dose of 900 mg/m2 IV over 90 minutes on days 1 and 8. Docetaxel will be administered at a dose of 75 mg/m2 IV over 60 minutes on day 8.
Study: NCT02521493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Given IM or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia chrysanthemi
Description: Given IM or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO
Study: NCT00003700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 300mg PO q day Days 1-14 Course I
Study: NCT01658995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline 100 mg oral capsules twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, one capsule orally twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
Study: NCT00998595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Promotora
Description: The Promotora will deliver education regarding postpartum follow-up and steps to take to decrease the risk for developing type 2 diabetes. The Promotora will clarify misperceptions and answer questions related to risk of developing diabetes and contraception. If the subject has barriers to accessing care with transportation or childcare, she will help the subjects to access existing resources. The Promotora will give the subject her contact information and will also contact the subject to remind her of her appointments and reschedule if she missed an appointment.
Study: NCT00912522

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: TRANSCRANIAL MAGNETIC STIMULATION

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: TRANSCRANIAL MAGNETIC STIMULATION
Study: NCT01090609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent implantation
Description: Stent implantation
Study: NCT00372216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel (Iscover/Plavix)
Description: Pre-hospital loading-dose of 600 mg Clopidogrel as early as possible
Study: NCT04269850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic fecal microbiota
Description: Single dose of capsules with fecal transplant (capsules for adults - 400-815mg, for adolescents - 280-500mg, for children - 160-320mg) - 2 capsules/kg body weight, divided in two consecutive days Additional supportive therapy after FMT include omeprazole 40mg po, inulin 1gr x 4 times a day po, metoclopramide 40mg po.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib starting dose 10 mg bid. In case of grade 4 hematological toxicity dose can be reduced by 25-75%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisone
Description: Methylprednisone starting dose 0.5 mg/kg bid IV or oral, with subsequent tapper by 0.1 mg/kg every 5 days.
Study: NCT04298034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetalol, Nifedipine
Description: Antihypertensive treatment that is safe and well studied in peripartum women.
Study: NCT01299987

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intraoperative radiotherapy
Description: intraoperative single dose radiotherapy (20 Gy)
Study: NCT00912522

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: TRANSCRANIAL MAGNETIC STIMULATION

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: TRANSCRANIAL MAGNETIC STIMULATION

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: TRANSCRANIAL MAGNETIC STIMULATION
Study: NCT03108820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TMH Intervention
Description: Home visits and close interaction with injured patient to assure plan for care is being followed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Review hospital discharge and rehabilitation plan, identification of primary care provider, provision of educational materials on communication skills, caregiver coping skills, and legal and financial advice.
Study: NCT01792453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spring water
Study: NCT01775722

Intervention type: DEVICE
Group type: OTHER
Intervention: Pulsed Dye Laser
Description: port wine stain

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined Bipolar Radiofrequency&Pulsed Dye Laser
Description: Combined Bipolar Radiofrequency\&Pulsed Dye Laser Treatment
Study: NCT03014414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fun First
Description: Learn key enjoyable maintenance skills before losing weight

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Watchers
Description: Focus on losing weight first via convenient meetings and personalized online tools
Study: NCT03790956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Silk Microparticle Filler Injection
Description: A silk protein microparticle-based filler will be injected deep to the thyroarytenoid muscle of the paralyzed vocal fold to augment/medialize its position.
Study: NCT04033510

Intervention type: OTHER
Intervention: Standard of Care Interventions to convert patient from atrial fibrillation to normal rhythm
Description: Direct current cardioversion, PVAI-atrial fibrillation ablation, Minimally Invasive Surgical Maze procedure, Medications
Study: NCT06400251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT00309738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin